| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-10-01 | 3.3 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |
| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-10-01 | 3.2 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |
| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-10-01 | 3.1 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |
| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-10-01 | 3.0 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |
| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-09-27 | 2.0 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |
| View | NM_002755.4(MAP2K1):c.158T>C (p.Phe53Ser) | Likely Pathogenic | RASopathy | 2024-09-27 | 1.0 | ClinGen RASopathy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MAP2K1 Version 2.1.0 | MAP2K1 |